Literature DB >> 21430014

Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines.

Ethan C Settembre1, Philip R Dormitzer, Rino Rappuoli.   

Abstract

Calls to develop a universal influenza vaccine have increased in the wake of the 2009 H1N1 influenza pandemic. This demand comes at a time when analyses of the human antibody repertoire, informed by structures of complexes between broadly neutralizing antibodies and influenza hemagglutinin, have revealed the target of a class of broadly neutralizing antibodies. Recent studies suggest a path forward to more broadly protective influenza vaccines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21430014     DOI: 10.1093/jmcb/mjq046

Source DB:  PubMed          Journal:  J Mol Cell Biol        ISSN: 1759-4685            Impact factor:   6.216


  4 in total

1.  Bringing influenza vaccines into the 21st century.

Authors:  Ethan C Settembre; Philip R Dormitzer; Rino Rappuoli
Journal:  Hum Vaccin Immunother       Date:  2013-12-30       Impact factor: 3.452

Review 2.  Molecular basis of the structure and function of H1 hemagglutinin of influenza virus.

Authors:  Nongluk Sriwilaijaroen; Yasuo Suzuki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

3.  Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.

Authors:  Natalija Budimir; Anke Huckriede; Tjarko Meijerhof; Louis Boon; Emma Gostick; David A Price; Jan Wilschut; Aalzen de Haan
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

4.  Immune history shapes specificity of pandemic H1N1 influenza antibody responses.

Authors:  Yang Li; Jaclyn L Myers; David L Bostick; Colleen B Sullivan; Jonathan Madara; Susanne L Linderman; Qin Liu; Donald M Carter; Jens Wrammert; Susanna Esposito; Nicola Principi; Joshua B Plotkin; Ted M Ross; Rafi Ahmed; Patrick C Wilson; Scott E Hensley
Journal:  J Exp Med       Date:  2013-07-15       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.